What changed from existing technology?
This study uses artificial intelligence to create a personalized treatment plan for a type of blood cancer called acute myeloid leukemia, helping doctors choose the best drugs and avoid resistance.
This is the first study to use AI to integrate multiple types of biological data to predict how patients will respond to a specific drug and develop strategies to overcome resistance in leukemia treatment.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
riptomic, epigenetic, and clinical features to predict patient-specific response to venetoclax and translate resistance-associated signals into actionable th
Abstract ↗acute myeloid leukemia. Acute myeloid leukemia (AML) remains difficult to treat because profound molecular heterogeneity enables rapid adaptive resistan
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This model could help doctors choose the best treatment for individual patients and develop new strategies to prevent drug resistance in leukemia.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.